While it may be true that a complete, standardized lipid panel should be performed for a first-time estimation of the overall ASCVD risk, dosing the plasmatic levels of ApoB and LDL subfractions could allow for a more complex evaluation of the atherogenic burden and could also provide a proper starting point for therapeutic management. Here, APOB is linked to atherosclerosis.